ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu(Yale University), Katerina Politi(Yale Cancer Center)
Cited by 24
Related Papers
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
|Proceedings of the National Academy of Sciences|2009|255
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
|Cancer Cell|2023|103
Challenges and opportunities for modeling aging and cancer
|Cancer Cell|2023|24
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
|The Journal of Experimental Medicine|2024|19